Oral GLP-1 analogues are the fastest-growing category, fueled by growing patient demand for easy-to-use needle-free substitutes
Zepbound quickly became one of the most talked-about weight loss medications in recent years
Phase 2 clinical trial data suggests retatrutide may produce greater weight loss (24.2 percent in 48 weeks) compared to semaglutide (14.9 percent in 68 weeks)
Across the Phase 2 trials, participants experienced an average systolic blood pressure decrease of 6.8 mmHg
Contact West Coast Plastic Surgery Center at (805) 983-1999 to schedule your consultation and discover how our Weight Loss Program can help you begin the new year on the right path.
The shortage-based legal exemption that underpinned widespread compounded semaglutide availability is no longer active for either 503A pharmacies or 503B outsourcing facilities Compounded GLP-1 programs operating today must navigate a legal framework that includes restrictions on compounding drugs that are commercially available drugs - meaning the compounding pharmacy's specific formulation, documentation, and prescriber individualization process matters for legal compliance The FDA still permits compounding under 503A for individual patient-specific prescriptions that involve a prescriber-documented "significant difference" from the commercially available product - but that requires specific clinical justification, not just a standard intake form Availability of specific compounded GLP-1 formulations may be affected by FDA enforcement actions, pharmacy-specific compliance status, and ongoing regulatory developments in this space None of this means compounded GLP-1 programs are operating illegally
